Immunisation for adults with HIV infection

Human immunodeficiency virus (HIV) infects CD4+ T cells leading to a progressive decline in CD4 cell count, increasing immunodeficiency and vulnerability to infection, and suboptimal responses to vaccines. Use of antiretroviral therapy (ART) to reduce virus replication and improve CD4 counts to 200 cells/mm$^3$ or higher, preferably above 400 cells/mm$^3$, is recommended to improve the response to all vaccines.

For children aged under 18 years, please refer to the Immunisation Handbook 2017 2nd Edition.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Notes</th>
<th>Additional notes</th>
<th>Recommended schedule</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| Influenza (Influvac® Tetra) | • Increased risk of complications | Administration notes  
  • Annually, during the Influenza Immunisation Programme | • Administer one dose annually | FUNDED |
| Hepatitis B (Engerix-B®) | • Increased risk of chronic disease  
  • Reduced vaccine seroconversion rates, particularly in individuals who are aged over 45 years, smoke tobacco products or who are not on ART  
  • Evidence of immunity  
  • Check serology 4–6 weeks after final dose  
  • If antiHBs <10 IU/L, seek advice from HIV specialist  
  • Non-responders  
  • A course of double-dose adult strength Engerix-B (i.e. 40 mcg) or Twinrix® may be considered | Recommended for  
  • Hepatitis B non-immune individuals  
  Evidence of immunity  
  • Check serology 4–6 weeks after final dose  
  • If antiHBs <10 IU/L, seek advice from HIV specialist  
  • Non-responders  
  • A course of double-dose adult strength Engerix-B (i.e. 40 mcg) or Twinrix® may be considered | If aged under 46 years and a non-smoker and on ART  
  • Administer three doses at 0, 1 and 6 months OR  
  If aged 46 years or older or a smoker or not on ART  
  • Administer four doses at 0, 1, 2 and 6 months | FUNDED  
  NOT funded  
  Double-dose of Engerix-B or Twinrix |
| Pneumococcal PCV13 (Prevenar 13®) | • Protection lasts longer than that from Pneumovax 23  
  • Generates long term memory cells that can produce additional protection following disease exposure | Administration notes  
  • Administer Prevenar 13 before Pneumovax 23  
  • A minimum of 4 weeks is required between administration of Prevenar 13 and Menactra (MVC4-D)  
  • If Pneumovax 23 (23PPV) has been administered before Prevenar 13, wait one year to give Prevenar 13 | • Administer one dose of Prevenar 13 | FUNDED |
| Pneumococcal 23PPV (Pneumovax® 23) | • Broadens protection against an additional 12 pneumococcal serotypes not covered by Prevenar 13  
  • Protection is shorter than that from Prevenar 13  
  • Does not generate memory cells  
  • Blunts/reduces the immune response to subsequent pneumococcal vaccinations | Administration notes  
  • Administer Pneumovax 23 (23PPV) a minimum of 8 weeks after Prevenar 13 | If aged 18 years to under 60 years  
  • Administer one dose  
  • Schedule a recall for the second dose in 5 years  
  • Schedule a recall for the third/final dose 5 years after second dose or at age 65 years, whichever is later  
  If aged 60 years or older  
  • Administer one dose  
  • Schedule a recall for the second/final dose in 5 years | FUNDED |

Continued on page 2...
## Immunisation for adults with HIV infection

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Notes</th>
<th>Additional notes</th>
<th>Recommended schedule</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| Human papillomavirus HPV             | • Increased risk of HPV related malignancy but less frequently serotypes 16 & 18 | **Recommended for:**  
• Males and females 18–45 years of age inclusively  
**Administration notes**  
• Check immunisation records/National Immunisation Register (NIR) for a primary course of HPV vaccines  
• Gardasil 9 is prescribed off-label for males aged 27–45 years inclusively. No safety concerns are expected. Vaccine efficacy is not expected to be significantly different to efficacy in females in the same age group. | **Administer three doses at 0, 2 and 6 months** | FUNDED up to 27 years of age  
Recommended NOT funded 27 years or older |
| (Gardasil®9)                         |                                                                      |                                                                                 | **Recommended NOT funded** | FUNDED |
| Meningococcal MCV4-D (Menactra®)     | • Increased risk of infection but not as high as for pneumococcal disease  
• Disease may be more severe | **Administration notes**  
• No NeisVac-C® (MenCCV) required  
• A minimum of 4 weeks is required between administration of Prevenar 13 (PCV13) and Menactra | **Administer two doses Menactra 8 weeks apart**  
**Schedule a precall for a booster dose every 5 years** | FUNDED |
| Hepatitis A (Havrix®)                | • Disease is not worse unless the individual also has hepatitis B or hepatitis C infection | **Highest risk groups**  
• MSM  
• Those travelling to hepatitis A risk countries  
• Illicit injection drug users  
• Coinfection with hepatitis B or hepatitis C | **Administer two doses 6 months apart**  
**Administer a booster dose every 10 years** | Recommended NOT funded |
| Tetanus/diphtheria/pertussis Tdap (Boostrix®) | • Duration of protection against tetanus/diphtheria and/ or pertussis may be shorter compared with healthy vaccinees | **Administration notes**  
• Check immunisation records for a primary course of three tetanus/diphtheria containing vaccines | **Incomplete primary course documented**  
• Administer funded adult catch-up vaccines to complete a three dose course of tetanus/diphtheria vaccines  
• Replace the first funded Td with non-funded Tdap  
• Administer two further funded Td at 4 weekly intervals  
• Schedule a precall for a Tdap dose every 10 years  
**Complete primary course documented**  
• If a minimum of 10 years has elapsed since receipt of a previous pertussis containing vaccine  
• Administer one non-funded Tdap dose  
• Schedule a precall for a Tdap dose every 10 years | NOT funded Tdap  
FUNDEN Td |

Continued on page 3...
## Immunisation for adults with HIV infection

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Notes</th>
<th>Additional notes</th>
<th>Recommended schedule</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| Measles/mumps/rubella MMR (Priorix®) | • Disease may be more severe | **Highest risk group**  
• Individuals born in 1969 or later who do not have two documented doses of MMR vaccine | If CD4+ lymphocyte count is ≥200 cells/mm³ (a,b,c,d) and administration of two doses at least 4 weeks apart | **CONTRAINDICATED** if CD4 count is <200 cells/mm³ (e) |
| Varicella (chickenpox) VV (Varilrix®) | • Disease may be more severe | **Highest risk groups**  
• Individual who do not have a reliable history of chickenpox disease  
• Individuals raised overseas, especially in subtropical countries  
**Evidence of immunity**  
• Individuals with a positive past history of chickenpox disease are considered immune to varicella zoster virus  
• If no reliable history of chickenpox disease  
  • Check varicella zoster virus serology  
  • If varicella zoster virus serology is negative (i.e. non-immune) administer funded varicella vaccine | If CD4+ lymphocyte count is ≥200 cells/mm³ (a,b,c,d), and The individual is varicella zoster virus seronegative (i.e. non-immune) 
• Administer two doses at least 4 weeks apart | **CONTRAINDICATED** if CD4 count is <200 cells/mm³ (e) |
| Herpes zoster HZV (Zostavax®) | • Increased risk of shingles and complications | **Administration notes**  
• Individuals aged 50 years or older with a positive past history of chickenpox disease or laboratory confirmation of immunity  
• If the individual does not have a reliable history of chickenpox disease, check varicella zoster virus serology | If CD4+ lymphocyte count is ≥200 cells/mm³ (a), and  
• The individual has a reliable history of chickenpox disease, or laboratory confirmation of varicella zoster virus immunity  
• Administer one dose of herpes zoster vaccine (HZV) OR  
If CD4+ lymphocyte count is ≥200 cells/mm³ (a), and  
• The individual is varicella zoster virus seronegative (i.e. non-immune) 
• Administer two doses of funded varicella vaccine (VV) at least 4 weeks apart | **CONTRAINDICATED** if CD4 count is <200 cells/mm³ (g) |

### Foot notes

a. Live viral vaccines are contraindicated with a CD4+ lymphocyte count under 200 cells/mm³.
b. Patients who have received immunoglobulin or other blood products may require time for passive antibodies to decrease prior to administration of live varicella and MMR vaccines. Refer to Table A6.1: Suggested intervals between immunoglobulin product administration or blood transfusion and MMR or varicella vaccination in the Immunisation Handbook 2017 2nd Edition.
c. Only a single live vaccine is recommended at each visit for individuals with HIV infection. A minimum interval of 4 weeks is required between live vaccine doses administered at different visits.
d. Consider normal immunoglobulin or zoster immunoglobulin for post-exposure measles or varicella prophylaxis respectively in non-immune individuals.
e. When an individual’s CD4+ lymphocyte count is 200 cells/mm³ or higher – MMR and varicella vaccines are FUNDED for individuals who meet the eligibility criteria.
f. Two doses of varicella vaccine are funded for a household contact of an individual who is not immune to varicella and is severely immunocompromised, where the household contact has no clinical history of varicella infection or immunisation.
g. When an individual’s CD4+ lymphocyte count is 200 cells/mm³ or higher – HZV is FUNDED for individuals aged 65–80 years. HZV is recommended but NOT funded for individuals aged 50–64 years or 81 years and older.